Breast CancerOpen to EnrollmentPhase 3

BREAST: PERI-OPERATIVE: TNBC: SCARLET

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

View on ClinicalTrials.gov Browse more trials

Study snapshot

Title: SWOG S2212 SCARLET Breast Cancer perioperative TNBC
Malignancy: Breast, IBC
Stage: Stage 3
Disease setting: Adjuvant/Post-surgical
Line of therapy: Peri-operative
Investigational agent: Carboplatin, Paclitaxel, Pembrolizumab
Drug class: Chemotherapy, PD-1 inhibitor
Principal investigator: Greg Vidal, MD, PhD
Sponsor: SWOG
Path: ER negative, PR negative, HER2 negative, TNBC
Randomized: Yes
ClinicalTrials.gov ID: NCT05929768

Eligibility and objectives

Key eligibility criteria details

ER-, PR-, HER2- TNBC
Clinical stage either
- T2-T4, N0, M0 or
- T1-T3, N1-2, M0
- No T4/N+, any N3, or inflammatory breast cancer
No prior systemic therapy for curative intent
No previous ipsilateral surgery for current breast surgery
ECOG PS 0-

Objective

Primary
- Breast cancer event free survival
Secondary
- Path CR
- Residual cancer burden
- Distant relapse-free survival
- OS
- Distant relapse-free interval
- RFS
- Safety
- QOL

Study snapshot

Eligibility and objectives

Key eligibility criteria details

Objective

Treatment details